Yet in the experience of the expert panel, despite the need for cost-effective anti-TNF-α treatments in IBD, supporting evidence for consistent outcomes, and endorsement from guiding bodies, the uptake of biosimilar anti-TNF-α medicines in practice has remained suboptimal. The gene discussed is TNF; the disease is inflammatory bowel disease.